Introduction
Tuberculosis (TB) is a chronic infectious disease caused by the bacterium Mycobacterium tuberculosis (MTB) and remains one of the leading causes of death worldwide, despite the availability of effective anti-TB drugs. 1 Globally, there were an estimated 10.4 million new TB cases and 2.0 million deaths due to the disease in 2016. 2 The number of new cases increased from 9 million in 2013 to 10.4 million in 2016.
The Global Adult Tobacco Survey (GATS) found that in 2015 there were 879 million current tobacco users, including 721 million men and 158 million women among GATS countries. 14 There is substantial evidence to suggest that tobacco smoking is associated with TB infection and disease: [15] [16] [17] [18] smokers have two-fold increased risk of TB infection and active TB. 16 , 17 Maurya et al 19 found that active smoking increases the risk of extrapulmonary TB. Cigarette smoking was not only strongly associated with an increased risk of TB, but also associated with the recurrence and severity of pulmonary TB. 18, 20, 21 Since both tobacco smoking and DR-TB are global problems, the association between tobacco smoking and DR-TB has attracted much attention from researchers. However, previous studies on the association between tobacco smoking and DR-TB were varied in regard to geographic region, ethnicity, and study design. Moreover, epidemiological data on this association have not been systematically reviewed. Therefore, we conducted a meta-analysis to determine whether tobacco smoking was an independent risk factor for DR-TB, and our results may help to guide health interventions.
Methods
This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) guidelines.
Search strategies
We searched the Ovid MEDLINE, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, WANFANG, and WEIPU databases to identify all published articles that evaluated the association between tobacco smoking and the risk of DR-TB, from their inception until September 16, 2017. The search terms were used as follows: "smok*" or "smoking" or "cigarette" or "tobacco" in combination with "drug-resistant tuberculosis" or "multidrug resistant tuberculosis" or "extensively drug resistant tuberculosis." The following criteria were used for selecting studies in the meta-analysis: 1) the study included patients with a diagnosis of TB; 2) the study evaluated the association between tobacco smoking and DR-TB; 3) the study design was cross-sectional, case-control, or cohort; and 4) adjusted odds ratios (ORs) or crude ORs and 95% CIs were reported or could be calculated. In addition, the following exclusion criteria were used: 1) abstracts or reviews; 2) studies on children aged <15 years; 3) studies conducted on animal models or not reporting the exposures/outcomes of interest; 4) repeated or overlapping publications; and 5) studies not in English or Chinese. For duplicate or overlapping publications, the study with the largest sample size or the latest to be published was included.
Data extraction and definitions
Two independent authors (Ming-Gui Wang and Yun-Xia Zhang) checked all potentially relevant studies and tried to reach a consensus on all items. Any disagreement was assessed by a third author (Miao-Miao Zhang). The following data were extracted from each study: first author, year of publication, location of the study population, age, study design, type of DR-TB (any DR-TB, M/XDR-TB), adjusted OR (or crude OR), and 95% CI. Any DR-TB was defined as MTB strains that show resistance to at least one of the anti-TB drugs, including monoresistant TB, polyresistant TB (resistant to two or more antibiotics), and M/XDR-TB. MDR-TB was defined as MTB strains that show resistance at least to rifampicin and isoniazid. MDR-TB with additional resistance to any fluoroquinolone and at least one of the three injectable second-line drugs was classified as XDR-TB. 
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Quality assessment
All selected studies in the meta-analysis were scored for methodological quality using the Newcastle-Ottawa Scale (NOS) (http://www.ohri.ca/programs/clinical_epidemiology/ oxford.asp). This scale uses a "star system" in which a study is judged on three broad perspectives: the selection of the study groups; the comparability of the groups; and the exposure for case-control or cross-sectional studies, or the outcome for cohort studies. The maximum score was 9 points. A score of <5 was considered low quality, 5-7 was considered medium quality, and >7 was considered high quality.
Statistical analysis
Since the included studies were conducted with different study designs and populations, the pooled ORs and 95% CIs were calculated using random effects models. Subgroup analyses were performed by study design (cross-sectional, case-control, and cohort), smoking type (past smoking, current smoking, and smoking history), DR-TB type (any DR-TB and M/ XDR-TB), and multivariate analysis (Yes or No). We assessed the heterogeneity among the studies by computing values for chi-square (Q), p-values (p<0.10 was considered statistically significant), and I 2 (values of 25%, 50%, and 75% were considered to represent low, medium, and high heterogeneity, respectively). 22 Sensitivity analysis was also performed to explore the sources of heterogeneity. The Begg rank correlation and Egger weighted regression test methods were also used to statistically assess publication bias (p< 0.05 was considered as indicative of statistically significant publication bias). STATA version 12.0 software (STATA Corporation, College Station, TX, USA) was utilized for all statistical analyses.
Results

Characteristics of studies included in the review
A total of 726 studies were identified after the initial search ( Figure 1 ). Of these, 663 were excluded after screening by titles and abstracts. The excluded studies were those that were duplicated papers, case reports, reviews, or unrelated studies. Of the remaining 63 articles, 12 studies were excluded Records identified from database searching (n=726)
Articles excluded based on title and abstract (duplicated studies, unrelated studies and those that were case reports, reviews, or conference abstracts) (n=663) 
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Wang et al owing to a lack of analysis of smoking and drug resistance, nine studies were excluded as they contained no extractable data, one study was conducted on animals, four studies were excluded as they were not in English or Chinese, three studies duplicated data, and one study did not include a drug susceptibility test. Finally, 33 articles were included in the systematic review and the meta-analysis. 10, 13, Of the 33 eligible studies, 23 were designed as case-control studies, five were cohort studies, and five were cross-sectional studies. The characteristics of all included studies are presented in Table 1 . The methodological quality was mixed as the NOS ranged from 5 to 8, as shown in Table 1 ; seven articles were awarded 8 stars, 19 studies were awarded 7 stars, six articles were awarded 6 stars, and one article was awarded 5 stars.
The association of smoking and drugresistant tuberculosis
The overall pooling result of all included studies is shown in Figure 2 , and there was a significant association between DR-TB and tobacco smoking (OR 1.57, 95% CI 1.33-1.86). We assessed heterogeneity using the I 2 statistic, and there was statistically significant heterogeneity observed among studies (p<0.001, I
2 =67.7%). Given the heterogeneity of the effect estimates, we conducted sensitivity analyses in which we compared pooled effect estimates for subgroups stratified on important study characteristics ( Table 2) . No evidence for substantial publication bias was found by either Begg's test (p=0.809) or Egger's test (p=0.099). The Begg's funnel plot is shown in Figure 3 .
Subgroup analyses were performed by study design, DR-TB type, smoking type, and whether multivariate analysis had been performed (in each analysis data were available from at least three studies for each subgroup) (Figures S1-S4), and the results are summarized in Table 2 . Stratification of the data by study design showed that the OR was 1.63 (95% CI 1.17-2.29) for cohort studies, 1.45 (95% CI 1.19-1.77) for case-control studies, and 2.44 (95% CI 1.32-4.49) for cross-sectional studies. Two subgroups were used for the type of DR-TB: any DR-TB (OR 1.70, 95% CI 1.3-2.23) and M/XDR-TB (OR 1.49, 95% CI 1.19-1.86). Significant associations were also observed in smoking type and multivariate analysis subgroup analysis (Table 2) . Heterogeneity was reduced in the cohort study group (p=0.265, I 2 =20.70%) compared with the overall pooled analysis.
Discussion
This systematic review and meta-analysis addressed the association of tobacco smoking and DR-TB using 33 selected studies. The results demonstrated that tobacco smoking was a significant independent risk factor for DR-TB regardless of study design, smoking status, and type of DR-TB. The subgroup analysis further showed that those exposed to tobacco smoking were found to have higher risks of M/XDR-TB than those who were not exposed.
To the best of our knowledge, this is the first metaanalysis to evaluate the association between tobacco smoking and DR-TB. Previous reviews had examined the association of tobacco smoking and TB, and the overall pooled summary data indicate that tobacco smoking is associated with an increased risk of TB infection and TB disease. 15, 17, 18 Active smoking was considered as a risk factor for TB recurrence and increased mortality due to TB. 16, 17 Smokers were also found to be at higher risk of extrapulmonary TB than nonsmokers. 19 However, whether tobacco smoking is associated with DR-TB had not been systematically reviewed previously.
TB patients who had a history of smoking exposure (regardless of whether they were current smokers or past smokers) were 1.57 times more likely to develop DR-TB compared with non-smoker TB cases. Our subgroup analyses indicated that current smokers had a 1.45-fold and past smokers had a 2.25-fold increased risk of DR-TB. Previous studies indicated that TB patients who are smokers are less likely to complete anti-TB treatment, 54, 55 which may lead to poor treatment outcome. It has been reported that 16.7% of unsuccessful treatment outcomes in Chinese patients were attributable to smoking. 56 Improving the treatment compliance of patients with TB is an effective way to reduce DR-TB and increase the cure rate. [56] [57] [58] Measures to promote smoking cessation may be an effective way to reduce DR-TB, TB relapse, and secondary transmission.
56,59
Another important finding of our study is the association between M/XDR-TB and tobacco smoking. The pooled risk of MDR-TB was 1.45 times higher in smokers than in non-smokers. Previous treatment, HIV infection, diabetes mellitus, low education, low income, and alcohol abuse have previously been associated with MDR-TB. 8, 9, 11, 58 The WHO has estimated that only 54% of patients with MDR/RR-TB and 30% of those with XDR-TB had a successful treatment outcome. 2 Owing to the poor outcome of M/XDR-TB treatment, it is important to reduce the occurrence of M/XDR-TB. Our findings suggest that, in addition to the usual benefits of smoking cessation, TB patients may benefit by reducing their risk of developing M/XDR-TB. 
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Heterogeneity analysis
The test for heterogeneity was statistically significant (I 2 =67.7%, p<0.001), indicating that there was considerable heterogeneity between studies. Unfortunately, we did not find any specific study that contributed a large portion of the heterogeneity in sensitivity analyses. Subgroup analyses showed that there was a significantly increased risk of DR-TB among smokers regardless of outcome definition (M/XDR-TB versus any DR-TB), type of study, smoking status, or type of analysis. As shown in Table 2 , the heterogeneity is mainly from study design and smoking type. Heterogeneity was low in the cohort studies (I 2 =20.70%, p=0.265) but high in case-control studies (I 2 =73.80%, p<0.001), most likely attributable to the quality of study design. When pooled estimates of studies grouped by the smoking type were compared, the heterogeneity was highest in the smoking history group (I 2 =70.10%, p<0.001), which did not distinguish between current smoking and past smoking. Although stratification by these study-specific variables did not fully explain the heterogeneity in the study, we consistently found a higher risk of DR-TB in TB patients with a smoking habit.
Limitations of the study
It is necessary to point out that although most of our included studies scored as high quality using the NOS, there are several potential limitations to this study. First, in this meta-analysis we only included studies published in English or Chinese, which may have resulted in a lack of data for four studies published in other languages, (Russian, Spanish, and Japanese). Although we failed to read the full text of these studies, associations between smoking and drug resistance could be discerned from the abstract of a study published in Russian, 60 and another in Spanish. 61 Second, we included data from different study designs, which may have led to the heterogeneity of the results. However, the similar positive association detected between smoking and DR-TB in cohort study subgroups, which are more liable to prove a cause-and-effect relationship than case-control and cross-sectional studies, reinforces our conclusion. Third, the assessment of tobacco smoking relied on self-reported behavior, which may not have been accurate because of recall error among TB patients. Furthermore, some studies did not distinguish between current smokers and past smokers, which may have led to inaccurate conclusions and contributed to the heterogeneity of the results. Fourth, studies employing both univariate and multivariate analysis were included. Univariate analysis may be influenced by other factors such as alcohol use, previous treatment of TB, primary or secondary DR, and diabetes. However, our results found Abbreviations: HDR-TB, isoniazid resistant tuberculosis; M/XDR-TB, multidrug-/extensively drug-resistant tuberculosis; AOR, adjusted odds ratio; NA, data not available in article; NOS, Newcastle-Ottawa Scale. 
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Wang et al similar ORs and heterogeneity between the univariate and multivariate analysis groups, which strengthens the reliability of our conclusion. Finally, the laboratory conditions and technical proficiency of medical staff vary in different areas, and these factors may limit the accuracy of DR testing.
Conclusion
Our meta-analysis indicates that tobacco smoking was positively and significantly associated with DR-TB. Subgroup analysis also showed that tobacco smoking was an independent risk factor for M/XDR-TB. These findings suggest that DR-TB control might benefit from interventions aimed at reducing tobacco use. In other words, additional efforts should be made to encourage TB patients to quit smoking once they are diagnosed.
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